Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;9(9):1481-1486.
doi: 10.1002/acn3.51642. Epub 2022 Aug 6.

Seroprevalence of anti-myelin oligodendrocyte glycoprotein antibodies in adults with myelitis

Ki Hoon Kim  1 , Su-Hyun Kim  1 , Jae-Won Hyun  1 , Yeseul Kim  2 , Hyewon Park  2 , Ho Jin Kim  1   2
Affiliations

Seroprevalence of anti-myelin oligodendrocyte glycoprotein antibodies in adults with myelitis

Ki Hoon Kim et al. Ann Clin Transl Neurol. 2022 Sep.

Abstract

Although myelitis is the second most common presentation in adults with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD), studies on MOG-IgG seroprevalence in patients with myelitis episodes are sparse. Herein, we investigated MOG-IgG seroprevalence in Korean adults who exhibited myelitis since 2017. Among 151 adults with acute myelitis, 11 (7.3%) tested positive for MOG-IgG by the initial screening and 10 (6.6%) patients were finally diagnosed with MOGAD during the study period. This study is the first to provide data on MOG-IgG seroprevalence in adults with myelitis and supports the clinical utility and importance of MOG-IgG testing in myelitis episodes.

PubMed Disclaimer

Conflict of interest statement

K. H. Kim, Y. Kim, and H. Park report no disclosures. S.‐H. Kim has lectured, consulted, and received honoraria from Bayer Schering Pharma, Biogen, Genzyme, Merck Serono, and UCB and received a grant from the National Research Foundation of Korea. J.‐W. Hyun has received a grant from the National Research Foundation of Korea. H. J. Kim received a grant from the National Research Foundation of Korea and research support from Aprilbio and Eisai; received consultancy/speaker fees from Alexion, Aprilbio, Biogen, Celltrion, Daewoong, Eisai, GC Pharma, HanAll BioPharma, Horizon Therapeutics (foremly Viela Bio), MDimune, Merck Serono, Novartis, Roche, Sanofi Genzyme, Teva‐Handok, and UCB; is a co‐editor for the Multiple Sclerosis Journal and an associate editor for the Journal of Clinical Neurology.

Figures

Figure 1
Figure 1
A flow diagram of patients. During the study period, 510 patients with CNS‐IDDs were newly registered, and 151 patients who fulfilled the inclusion criteria were selected. CNS‐IDDs, inflammatory demyelinating diseases of the central nervous system.
See this image and copyright information in PMC

References

    1. Marignier R, Hacohen Y, Cobo‐Calvo A, et al. Myelin‐oligodendrocyte glycoprotein antibody‐associated disease. Lancet Neurol. 2021;20(9):762‐772. - PubMed
    1. Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B. Neuromyelitis optica. Nat Rev Dis Primers. 2020;6(1):85. - PubMed
    1. Jarius S, Ruprecht K, Kleiter I, et al. MOG‐IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long‐term outcome. J Neuroinflammation. 2016;13(1):280. - PMC - PubMed
    1. Hyun JW, Lee HL, Jeong WK, et al. Comparison of MOG and AQP4 antibody seroprevalence in Korean adults with inflammatory demyelinating CNS diseases. Mult Scler. 2021;27(6):964‐967. - PubMed
    1. Cobo‐Calvo A, Sepúlveda M, Rollot F, et al. Evaluation of treatment response in adults with relapsing MOG‐Ab‐associated disease. J Neuroinflammation. 2019;16(1):134. - PMC - PubMed

Publication types

Substances

LinkOut - more resources